Signal Desk · Companies

Glenmark launches generic Inlyta tablets in the US

2026-11-16 · 1 source · Business Standard Companies

In short

Glenmark Pharmaceuticals Inc, USA, launched Axitinib tablets in 1 mg and 5 mg strengths on Monday in the US. The medicine is a generic version of Pfizer's Inlyta and is used for advanced kidney cancer.

The company says the launch helps it give patients in the United States more affordable treatment options.

What the reporting says

Glenmark Pharmaceuticals Inc, USA, announced the launch of Axitinib Tablets in 1 mg and 5 mg strengths in the US on Monday, a generic version of Pfizer Inc's Inlyta tablets. The tablets are used to treat advanced renal cell carcinoma, a type of kidney cancer. The company said the launch supports its push to expand access to affordable medicines in the United States.

Why it matters

Glenmark Pharmaceuticals Inc, USA, added Axitinib tablets in 1 mg and 5 mg strengths to its US portfolio on Monday. The generic version of Pfizer's Inlyta is used for advanced renal cell carcinoma, which is kidney cancer. The move expands Glenmark's presence in the US generic medicines market and targets patients seeking lower-cost treatment options.

Touches: Glenmark Pharmaceuticals Inc, Pfizer Inc, Healthcare, Companies

Sources